National Academies Press: OpenBook
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

IMPLEMENTING A
NATIONAL CANCER
CLINICAL TRIALS SYSTEM
FOR THE 21ST CENTURY

Second Workshop Summary

An American Society of Clinical Oncology and

Institute of Medicine Workshop

Sharyl J. Nass and Margie Patkak, Rapporteurs

National Cancer Policy Forum

Board on Health Care Services

INSTITUTE OF MEDICINE

OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS
Washington, D.C.
www.nap.edu

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

THE NATIONAL ACADEMIES PRESS     500 Fifth Street, NW     Washington, DC 20001

NOTICE: The workshop that is the subject of this workshop summary was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

This project was co-sponsored by the American Society of Clinical Oncology. The National Cancer Policy Forum is also supported by Contract Nos. HHSN261200900003C and 200-2011-38807 between the National Academy of Sciences and the National Cancer Institute and the Centers for Disease Control and Prevention, respectively, and by the American Association for Cancer Research, the American Cancer Society, the American Society for Radiation Oncology, the American Society of Clinical Oncology, the Association of American Cancer Institutes, Bristol-Myers Squibb, C-Change, the CEO Roundtable on Cancer, GlaxoSmithKline, LIVESTRONG, Novartis Oncology, the Oncology Nursing Society, and Sanofi Oncology. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for the activity.

International Standard Book Number-13: 978-0-309-28724-1
International Standard Book Number-10: 0-309-28724-3

Additional copies of this report are available for sale from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; http://www.nap.edu.

For more information about the Institute of Medicine, visit the IOM home page at: www.iom.edu.

Copyright 2013 by the National Academy of Sciences. All rights reserved.

Printed in the United States of America

The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The serpent adopted as a logotype by the Institute of Medicine is a relief carving from ancient Greece, now held by the Staatliche Museen in Berlin.

Suggested citation: IOM (Institute of Medicine). 2013. Implementing a national cancer clinical trials system for the 21st century: Second workshop summary. Washington, DC: The National Academies Press.

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

“Knowing is not enough; we must apply.
Willing is not enough; we must do.”

—Goethe

image

INSTITUTE OF MEDICINE

           OF THE NATIONAL ACADEMIES

Advising the Nation. Improving Health.

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences.

The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. C. D. Mote, Jr., is president of the National Academy of Engineering.

The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine.

The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Ralph J. Cicerone and Dr. C. D. Mote, Jr., are chair and vice chair, respectively, of the National Research Council.

www.national-academies.org

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

WORKSHOP PLANNING COMMITTEE1

MONICA BERTAGNOLLI (Chair), Professor of Surgery, Harvard University Medical School, Boston, MA, and Chair, Alliance for Clinical Trials in Oncology

AMY P. ABERNETHY, Associate Professor of Medicine, Duke University School of Medicine, and Director, Duke Cancer Care Research Program, Durham, NC

MICHAEL A. CALIGIURI, Director, Ohio State Comprehensive Cancer Center, Columbus, and President, Association of American Cancer Institutes

RENZO CANETTA, Vice President, Oncology Global Clinical Research, Bristol-Myers Squibb, Wallingford, CT

MICHAELE CHAMBLEE CHRISTIAN, Retired, Washington, DC

JAMES H. DOROSHOW, Deputy Director for Clinical and Translational Research, National Cancer Institute, Bethesda, MD

PATRICK GAVIN, President, Patrick Gavin R.Ph. Consulting LLC, Marne, MI

GREGORY H. REAMAN, Associate Director for Oncology Sciences, Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD

GEORGE W. SLEDGE, JR., Chief of Oncology, Department of Medicine, Stanford University, CA

RALPH R. WEICHSELBAUM, Chair, Radiation and Cellular Oncology, and Director, Ludwig Center for Metastasis Research, University of Chicago Medical Center, IL

ROBIN ZON, Partner and Vice President, Michiana Hematology-Oncology, and Principal Investigator, Northern Indiana Cancer Research Consortium–Community Clinical Oncology Program, South Bend, IN

________________

1 Institute of Medicine planning committees are solely responsible for organizing the workshop, identifying topics, and choosing speakers. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

IOM Project Staff

SHARYL J. NASS, Director, National Cancer Policy Forum

PAMELA LIGHTER, Research Assistant

MICHAEL PARK, Senior Program Assistant

CHER HUANG, Summer Intern, MIT in Washington Program (May-August 2013)

ROGER HERDMAN, Director, Board on Health Care Services

American Society of Clinical Oncology Project Staff

SUANNA BRUINOOGE, Director, Research Policy Division, Cancer Policy and Clinical Affairs Department

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

NATIONAL CANCER POLICY FORUM1

JOHN MENDELSOHN (Chair), Director, Khalifa Institute for Personalized Cancer Therapy, MD Anderson Cancer Center, Houston, TX

PATRICIA A. GANZ (Vice Chair), Professor, University of California, Los Angeles, School of Medicine & Public Health, Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Center

AMY P. ABERNETHY, Associate Professor of Medicine, Duke University School of Medicine, and Director, Duke Cancer Care Research Program, Durham, NC

RAFAEL G. AMADO, Senior Vice President and Head of R&D, GlaxoSmithKline-Oncology, Collegeville, PA

FRED APPELBAUM, Director, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

PETER B. BACH, Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY

EDWARD BENZ, JR., President, Dana-Farber Cancer Institute and Director, Harvard Cancer Center, Harvard School of Medicine, Boston, MA

MONICA BERTAGNOLLI, Professor of Surgery, Harvard University Medical School, Boston, MA

OTIS BRAWLEY, Chief Medical Officer and Executive Vice President, American Cancer Society, Atlanta, GA

MICHAEL A. CALIGIURI, Director, Ohio State Comprehensive Cancer Center, Columbus

RENZO CANETTA, Vice President, Oncology Global Clinical Research, Bristol-Myers Squibb, Wallingford, CT

MICHAELE CHAMBLEE CHRISTIAN, Retired, Washington, DC

WILLIAM DALTON, CEO, M2Gen Personalized Medicine Institute, Moffitt Cancer Center, Tampa, FL, and Chair, American Association for Cancer Research Science Policy & Legislative Affairs Committee

________________

1 Institute of Medicine forums and roundtables do not issue, review, or approve individual documents. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.

Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

WENDY DEMARK-WAHNEFRIED, Associate Director for Cancer Prevention and Control, University of Alabama at Birmingham Comprehensive Cancer Center

ROBERT ERWIN, President, Marti Nelson Cancer Foundation, Davis, CA

CAROL HAHN, Medical Director of Radiation Oncology, Duke University Medical Center, Raleigh, NC

ROY S. HERBST, Chief of Medical Oncology, Yale Cancer Center, New Haven, CT

THOMAS J. KEAN, President and CEO, C-Change, Washington, DC

MICHELLE M. LE BEAU, Arthur and Marian Edelstein Professor of Medicine and Director, Comprehensive Cancer Center, University of Chicago, IL, and President, Association of American Cancer Institutes

DOUGLAS R. LOWY, Deputy Director, National Cancer Institute, Bethesda, MD

DANIEL R. MASYS, Affiliate Professor, Biomedical Informatics, University of Washington, Seattle

MARTIN J. MURPHY, Chief Executive Officer, CEO Roundtable on Cancer, Durham, NC

BRENDA NEVIDJON, Clinical Professor and Specialty Director, Nursing & Healthcare Leadership, Duke University School of Nursing, Durham, NC, and Past President, Oncology Nursing Society

STEVEN PIANTADOSI, Director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA

RUTH RECHIS, Vice President of Programs, LIVESTRONG Foundation, Austin, TX

LISA C. RICHARDSON, Associate Director for Science, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA

DEBASISH ROYCHOWDHURY, Senior Vice President, Global Oncology, Sanofi Oncology, Cambridge, MA

YA-CHEN TINA SHIH, Director, Program in the Economics of Cancer, University of Chicago, IL

ELLEN SIGAL, Chairperson and Founder, Friends of Cancer Research, Washington, DC

STEVEN STEIN, Senior Vice President, U.S. Clinical Development and Medical Affairs, Novartis Oncology, East Hanover, NJ

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

JOHN A. WAGNER, Vice President, Clinical Pharmacology, Merck and Company, Inc., Rahway, NJ

RALPH R. WEICHSELBAUM, Chair, Radiation and Cellular Oncology, and Director, Ludwig Center for Metastasis Research, University of Chicago Medical Center, IL

JANET WOODCOCK, Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD

National Cancer Policy Forum Staff

SHARYL J. NASS, Director

LAURA LEVIT, Program Officer

ERIN BALOGH, Associate Program Officer

PAMELA LIGHTER, Research Assistant

MICHAEL PARK, Senior Program Assistant

CHER HUANG, Summer Intern, MIT in Washington Program (May-August 2013)

PATRICK BURKE, Financial Associate

SHARON B. MURPHY, Scholar in Residence

ROGER HERDMAN, Director, Board on Health Care Services

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

This page intentionally left blank.

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

Reviewers

This workshop summary has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise, in accordance with procedures approved by the National Research Council’s Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published workshop summary as sound as possible and to ensure that the workshop summary meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the process. We wish to thank the following individuals for their review of this workshop summary:

JAN BUCKNER, Chair and Professor, Department of Oncology, Mayo Clinic

BARBARA CONLEY, Associate Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute

MARY LOU SMITH, Co-founder, Research Advocacy Network

Although the reviewers listed above have provided many constructive comments and suggestions, they did not see the final draft of the workshop summary before its release. The review of this report was overseen by

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

JOHANNA T. DWYER, Professor of Medicine and Community Health, Tufts University School of Medicine, and Senior Nutrition Scientist, National Institutes of Health. Appointed by the Institute of Medicine, she was responsible for making certain that an independent examination of this report was carried out in accordance with institutional procedures and that all review comments were carefully considered. Responsibility for the final content of this report rests entirely with the rapporteurs and the institution.

Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

Acknowledgments

We thank the American Society of Clinical Oncology for generously co-sponsoring this workshop. The support of the many sponsors of the Institute of Medicine’s National Cancer Policy Forum was crucial to the planning and conduct of this workshop. Federal sponsors are the National Cancer Institute and the Centers for Disease Control and Prevention. Non-federal sponsors include the American Association for Cancer Research, the American Cancer Society, the American Society for Radiation Oncology, the American Society of Clinical Oncology, the Association of American Cancer Institutes, Bristol-Myers Squibb, C-Change, the CEO Roundtable on Cancer, GlaxoSmithKline, LIVESTRONG, Novartis Oncology, the Oncology Nursing Society, and Sanofi Oncology.

The Forum wishes to express its gratitude to the expert speakers whose presentations helped define the challenges and opportunities in implementing a national cancer clinical trials system. The Forum also wishes to thank the members of the planning committee for their work in developing an excellent workshop agenda.

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

This page intentionally left blank.

Page xviii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

This page intentionally left blank.

Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R1
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R2
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R3
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R4
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R5
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R6
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R7
Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R8
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R9
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R10
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R11
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R12
Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R13
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R14
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R15
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R16
Page xvii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R17
Page xviii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page R18
Next: Implementing a National Cancer Clinical Trials System for the 21st Century »
Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary Get This Book
×
Buy Paperback | $38.00 Buy Ebook | $30.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The National Clinical Trials Network (NCTN) supported by the National Cancer Institute (NCI) has played an integral role in cancer research and in establishing the standard of care for cancer patients for more than 50 years. Formerly known as the NCI Clinical Trials Cooperative Group Program, the NCTN is comprised of more than 2,100 institutions and 14,000 investigators, who enroll more than 20,000 cancer patients in clinical trials each year across the United States and internationally.

Recognizing the recent transformative advances in cancer research that necessitate modernization in how cancer clinical trials are run, as well as inefficiencies and other challenges impeding the national cancer clinical trials program, the NCI asked the IOM to develop a set of recommendations to improve the federally funded cancer clinical trials system. These recommendations were published in the 2010 report, A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program.
In early 2011, the NCPF and the American Society of Clinical Oncology (ASCO) held a workshop in which stakeholders discussed the changes they planned to implement in response to the IOM goals and recommendations. Two years later, on February 11-12, 2013, in Washington, DC, the NCPF and ASCO reconvened stakeholders to report on the changes they have made thus far to address the IOM recommendations. At this workshop, representatives from the NCI, the NCTN, comprehensive cancer centers, patient advocacy groups, the Food and Drug Administration (FDA), industry, and other stakeholders highlighted the progress that has been made in achieving the goals for a reinvigorated national cancer clinical trials system. Implementing a National Cancer Clinical Trials System for the 21st Century is a summary of that workshop.
  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!